德国拜耳利伐沙班的最新价格

It is a new type of oral anticoagulant drug. It was approved for marketing in the European Union in September 2008 and entered my country in 2009. It is the first Factor Xa inhibitor developed and launched by Bayer Pharmaceuticals after 10 years of research and development. It is mainly used to treat venous thrombosis in adults.

Many people have heard of Bayer in Germany. This is a large global company with core competitiveness in health care, agriculture and high-tech raw materials. Bayer has 750 manufacturing plants in 200 locations on six continents, and the company's product range exceeds 10,000 types. Products such as aspirin and heroin are produced by Bayer Pharmaceuticals.

Rivaroxaban produced by Bayer in Germany has the advantages of high bioavailability, long action time, safety and effectiveness. Compared with traditional warfarin, rivaroxaban does not require monitoring of coagulation and is a very good anticoagulant drug. Rivaroxaban produced by Bayer has been on the market for many years. Many patients have benefited from rivaroxaban treatment. So what is the price of rivaroxaban?

The current price of rivaroxaban in my country has been relatively reduced a lot. The price may be slightly different in different pharmacies in the country. However, the cheaper version currently on the market is the version exported to Turkey by Bayer from Germany. There are two specifications, 20mg*28 tablets priced at around 350$, and 15mg*28 tablets also priced at around 350$. The price may change due to various factors such as exchange rates. Please consult the Medical Companion Travel Service for details.

If you need the Turkish version and it is inconvenient to go abroad, you can also purchase it through Medical Travel Overseas Medical Consulting Service Company. Medical Travel is a company specializing in transnational medical consulting. It focuses on finding global high-quality medical resources for Chinese patients so that domestic patients can enjoy high-quality medical services.

Recommended related hot articles: /newsDetail/89908.html